Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Dutch bladder cancer cohort aims to map survival and recurrence

NCT ID NCT04503577

NEW Knowledge-focused Sponsor: Prospective Bladder Cancer Infrastructure Foundation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

Researchers in the Netherlands are building a nationwide cohort of adults with high-risk non-muscle-invasive, muscle-invasive, and metastatic bladder cancer. The study follows participants over time to measure overall survival, progression-free survival, recurrence-free survival, and health-related quality of life. It is designed as an infrastructure that can support both observational and interventional bladder cancer research. Participation does not prevent patients from joining other studies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If it succeeds, this infrastructure could give researchers a large, long-term dataset to test new bladder cancer treatments and better predict how the disease behaves.
What could go wrong
This is an observational cohort, not a treatment trial, so it cannot prove that any therapy works. Results depend on long-term follow-up, and patients who drop out or move away may weaken the data.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 3,600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2020

Expected to finish

Dec 2041

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Bladder cancer patients with high-risk non-muscle-invasive bladder cancer (T1, Tis or Ta+cis), muscle-invasvie bladder cancer (T2-4, any N, M0/X), and metastatic bladder cancer (any T, any N, M1a/b)

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Bladder cancer * Any stage except Ta * 18 years or older * Written informed consent Exclusion Criteria: * No exclusion criteria Note: participation in ProBCI does not exclude the patient from participation in other studies.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bladder cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

superficial urinary bladder carcinoma urinary bladder cancer urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bladder cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    23 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Albert Schweitzer Hospital

    RECRUITING

    Dordrecht, Netherlands

  • Alrijne Ziekenhuis

    RECRUITING

    Leiderdorp, Netherlands

  • Amphia Ziekenhuis

    RECRUITING

    Breda, Netherlands

  • Amsterdam UMC, location VUMC

    RECRUITING

    Amsterdam, Netherlands

  • Canisius Wilhelmina Ziekenhuis

    RECRUITING

    Nijmegen, Netherlands

  • Elisabeth-TweeSteden Ziekenhuis

    RECRUITING

    Tilburg, Netherlands

  • Erasmus Medical Center

    RECRUITING

    Rotterdam, Netherlands

  • Isala

    RECRUITING

    Zwolle, Netherlands

  • Jeroen Bosch Hospital

    RECRUITING

    's-Hertogenbosch, Netherlands

  • Maastricht University Medical Center

    RECRUITING

    Maastricht, Netherlands

  • Meander Medical Center

    RECRUITING

    Amersfoort, Netherlands

  • Medisch Centrum Leeuwarden

    RECRUITING

    Leeuwarden, Netherlands

  • Radboud univerisity Medical Center

    RECRUITING

    Nijmegen, Netherlands

  • Rijnstate

    RECRUITING

    Arnhem, Netherlands

  • SKB Winterswijk

    RECRUITING

    Winterswijk, Netherlands

  • Spaarne Gasthuis

    NOT_YET_RECRUITING

    Hoofddorp, Netherlands

  • Treant Hospital

    RECRUITING

    Emmen, Netherlands

  • University Medical Center Groningen

    RECRUITING

    Groningen, Netherlands

  • University Medical Center Utrecht

    RECRUITING

    Utrecht, Netherlands

  • VieCuri

    RECRUITING

    Venlo, Netherlands

  • ZGT

    RECRUITING

    Almelo, Netherlands

  • Ziekenhuis Gelderse Vallei

    RECRUITING

    Ede, Netherlands

  • Zuyderland

    RECRUITING

    Sittard, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.